KDR and neoplasm: Ivonescimab simultaneously blocks the binding of PD-1 to its ligand (PD-L1), thereby alleviating PD-1/PD-L1-mediated immunosuppression, and the binding of vascular endothelial growth factor (VEGF)-A to its receptor (VEGFR2), thereby blocking tumor angiogenesis in the tumor microenvironment (36).